CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.1% Today

What is CRISPR Therapeutics AG?

CRISPR Therapeutics AG (CRSP) operates in the biotech industry and is listed on the NASDAQ. The company specializes in developing gene-based medicines for severe diseases.

Why is CRISPR Therapeutics AG going down?

CRSP stock is down 5.1% on Mar 27, 2026 17:36

• Truist Financial recently upgraded CRISPR Therapeutics to a "Strong-Buy" rating. However, despite this upgrade, the stock experienced a bearish movement, hinting at other underlying factors impacting its performance.
• Despite some insider selling and recent financial misses, analysts maintain a positive outlook on CRISPR Therapeutics, citing advancements in its pipeline as a driving factor.
• The CEO's reception of significant equity awards and share sales for tax purposes could have influenced the bearish trend, potentially sparking concerns among investors regarding the company's financial stability.
• CRISPR Therapeutics has outperformed the broader market, indicating ongoing investor optimism regarding potential future enhancements in earnings and revenue, notwithstanding recent challenges faced by the company.

CRSP Price Chart

CRSP Technical Analysis

CRSP News

Truist Financial Upgrades CRISPR Therapeutics (NASDAQ:CRSP) to "Strong-Buy"

Truist Financial has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to a "Strong-Buy" rating, joining other analysts with bullish outlooks despite a recent earnings miss and a 97.8% year-over-year revenue decline. The stock maintains a consensus "Moderate Buy" rating with a $64.53 price target, although significant insider selling has occurred recently. Analysts cite pipeline optimism as a key factor for the continued positive ratings.

https://www.marketbeat.com/instant-alerts/truist-financial-upgrades-crispr-therapeutics-nasdaqcrsp-to-strong-buy-2026-03-26/

CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it

The article discusses CRISPR Therapeutics AG (CRSP) as a trending stock, providing essential information investors should consider before making a decision. It highlights key facts that could influence its stock performance.

https://www.msn.com/en-us/money/topstocks/crispr-therapeutics-ag-crsp-is-a-trending-stock-facts-to-know-before-betting-on-it/ar-AA1Zj4iH

Why CRISPR Therapeutics AG (CRSP) Performed Better Than the Market Today

CRISPR Therapeutics AG (CRSP) outperformed the broader market, rising 1.42% while the S&P 500, Dow, and Nasdaq saw smaller gains. Despite a recent monthly decline, investors are anticipating strong upcoming earnings with projected year-over-year EPS and revenue improvements. The company's stock currently holds a Zacks Rank of #3 (Hold) within the Medical - Biomedical and Genetics sector.

https://www.bitget.com/amp/news/detail/12560605305073

CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 3,182 Shares

CRISPR Therapeutics General Counsel James Kasinger sold 3,182 shares of the company's stock for approximately $148,854, reducing his stake by 3.26%. This sale comes as the company reported an earnings and revenue miss, with EPS of ($1.37) against an expected ($1.15) and revenue significantly below estimates. Analysts currently have a "Hold" rating on CRISPR Therapeutics with a consensus price target of $64.53, despite a mix of Buy, Hold, and Sell recommendations.

https://www.marketbeat.com/instant-alerts/crispr-therapeutics-nasdaqcrsp-general-counsel-james-kasinger-sells-3182-shares-2026-03-25/

CRISPR Therapeutics (CRSP) CEO gets major equity awards, sells shares for taxes

CRISPR Therapeutics CEO Samarth Kulkarni received significant equity awards, including a stock option for 114,249 common shares and 81,875 new restricted stock units, and also had 19,687 restricted stock units vest. Concurrently, Kulkarni sold 10,020 common shares for $46.78 each to cover tax withholding obligations associated with the RSU vesting, as per company policy. After these transactions, Kulkarni holds 255,501 common shares directly, with some still under a lock-up agreement.

https://www.stocktitan.net/sec-filings/CRSP/form-4-crispr-therapeutics-ag-insider-trading-activity-ee0c29129960.html

Trending Today

Paycom Software Inc. ($PAYC) Stock Forecast: Down 5.1% Today

Entergy Corporation ($ETR) Stock Forecast: Up 7.0% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Down 5.7% Today

Crude Oil ($CRUDE) Commodity Forecast: Up 6.2% Today

Norwegian Cruise Line Holdings Ltd. ($NCLH) Stock Forecast: Down 6.5% Today

Align Technology Inc. ($ALGN) Stock Forecast: Down 6.1% Today

Carnival Corporation ($CCL) Stock Forecast: Down 5.6% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.0% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.4% Today

Clean Energy Fuels Corp. ($CLNE) Stock Forecast: Up 8.1% Today

CRISPR Therapeutics AG Price History

13.01.2026 - CRSP Stock was up 11.3%

• Despite lower-than-anticipated Q4 revenue, CRISPR Therapeutics (CRSP) witnessed a significant upward trend in the market, reflecting investor confidence in the company's future prospects.
• The publication of the 2025 10-K report, outlining notable achievements and progress in its therapeutic initiatives, likely bolstered investor trust and contributed to the positive market movement.
• A favorable business update, highlighting advancements in various clinical programs and revenue growth associated with CASGEVY, may have eclipsed the Q4 revenue shortfall, fostering increased investor positivity.
• On the whole, the market dynamics indicate that investors are placing greater emphasis on CRISPR Therapeutics' upcoming potential and pipeline advancements rather than short-term financial performance, propelling the stock price upwards.

12.02.2026 - CRSP Stock was down 5.1%

• The increase in the convertible notes offering from $350 million to $550 million indicates strong investor demand and a strategic move to bolster financial flexibility for CRISPR Therapeutics.
• Cathie Wood's ARK Invest buying a significant stake in CRSP suggests confidence in the long-term potential of the company despite the bearish market movement.
• The stock's 12% decline following the convertible notes announcement may be attributed to short-term concerns about potential shareholder dilution, although analysts view this as a buying opportunity for investors with a higher risk tolerance.
• Overall, the market reaction seems to be a mix of short-term profit-taking due to fundraising news and long-term optimism about CRISPR Therapeutics' gene-editing platform and drug pipeline.

27.02.2026 - CRSP Stock was down 5.1%

• Truist Financial recently upgraded CRISPR Therapeutics to a "Strong-Buy" rating. However, despite this upgrade, the stock experienced a bearish movement, hinting at other underlying factors impacting its performance.
• Despite some insider selling and recent financial misses, analysts maintain a positive outlook on CRISPR Therapeutics, citing advancements in its pipeline as a driving factor.
• The CEO's reception of significant equity awards and share sales for tax purposes could have influenced the bearish trend, potentially sparking concerns among investors regarding the company's financial stability.
• CRISPR Therapeutics has outperformed the broader market, indicating ongoing investor optimism regarding potential future enhancements in earnings and revenue, notwithstanding recent challenges faced by the company.

10.02.2026 - CRSP Stock was down 5.6%

• CRISPR Therapeutics AG (CRSP) is rated as a "Moderate Buy" by Wall Street analysts with a 17% upside potential. Nonetheless, certain AI stocks are viewed as having greater potential with lower risk, potentially drawing investor interest elsewhere.
• Investor attention is increasingly focused on CRSP's valuation, anticipating higher revenue from Casgevy but expressing concerns about significant company losses. The undervaluation potential noted in a discounted cash flow model adds a layer of complexity to the stock's current performance.
• Notable institutional holdings changes include SR One Capital Management LP boosting its stake by 94.4%, while Citigroup Inc. reduced its position by 59.3%. These contrasting actions suggest varying outlooks on CRSP's future.
• ARK Investment Management LLC trimmed its stake in CRSP by 3.9%, yet it remains the 8th largest position in its portfolio. This adjustment, along with other institutional investors and insider selling, likely contributed to today's bearish stock movement.

24.01.2026 - CRSP Stock was up 6.3%

• A notable acquisition of shares by O Neil Global Advisors Inc. suggests confidence in CRISPR Therapeutics' long-term potential, contributing to the bullish movement.
• The FDA's RMAT designation for zugo-cel and progress in the gene-editing pipeline are viewed as positive catalysts, overshadowing the wider losses reported by the company.
• A reduction in stake by Vestmark Advisory Solutions Inc. following an earnings miss and revenue decline may have initially raised concerns, but investors appear reassured by the focus on future clinical advancements and pipeline momentum.
• Insider selling by the General Counsel post-earnings report may have initially caused uncertainty, but overall market sentiment appears optimistic about CRSP's growth prospects.

11.01.2026 - CRSP Stock was down 6.2%

• Recent performance shows CRSP shares lagging by -18.7% over the past month compared to the Zacks S&P 500 composite, likely influencing the downward movement.
• CEO Samarth Kulkarni's sale of 60,000 shares, reducing his stake to 4.3% of the company, could suggest doubts about short-term performance.
• Despite favorable evaluations from analysts and institutions, uncertainties around forthcoming earnings and potential revenue growth in the upcoming fiscal year may have prompted profit-taking and the stock's bearish trajectory.

05.01.2026 - CRSP Stock was down 6.3%

• Despite optimistic expectations and the possibility of surpassing earnings projections, CRSP faced a bearish trend, potentially linked to investors taking profits following a recent price target increase.
• The expected decrease in earnings per share for the quarter may have also contributed to the negative market sentiment, as investors may have been looking for stronger financial results.
• Despite indicators like pipeline growth and strong institutional support, such as ARK Investment Management, pointing towards a promising future for the company, the current market reaction may stem from short-term worries or general market volatility.
• The bearish movement could also be influenced by the high-risk nature of gene-editing technologies and the uncertainties surrounding the company's ongoing projects and financial results.

05.02.2026 - CRSP Stock was down 5.3%

• An increased stake by Vanguard Group Inc. amidst CRISPR Therapeutics missing quarterly earnings and revenue expectations could indicate a lack of confidence in the company's short-term performance.
• A significant reduction in stake by Contrarius Group Holdings Ltd and TD Asset Management Inc. might suggest concerns about CRSP's future prospects or management decisions.
• Despite an increased stake by Rafferty Asset Management LLC, mixed analyst ratings and notable insider selling, including by the CEO, could be contributing to the bearish movement in CRSP's stock price.
• The overall market sentiment seems to be cautious towards CRISPR Therapeutics AG due to the company's recent financial performance and insider activities, overshadowing its potential future growth prospects highlighted in the Simply Wall St analysis.

26.01.2026 - CRSP Stock was up 2.8%

• Despite recording a substantial year-over-year decline in earnings and revenue in Q4, CRISPR Therapeutics AG saw a bullish market shift.
• Institutional investors such as O Neil Global Advisors Inc. purchased a large number of shares, indicating confidence in the company's future prospects.
• The FDA's approval of zugo-cel as a Regenerative Medicine Advanced Therapy (RMAT) and the launch of Casgevy are viewed as pivotal factors driving positive investment sentiment, overshadowing concerns about widening net losses.
• Varied analyst ratings and insider selling may have introduced some volatility, but overall, market attention appears to be more drawn towards the company's pipeline progress and upcoming milestones rather than its current financial results.

06.01.2026 - CRSP Stock was up 5.1%

• Positive ratings from Citizens and Bank of America suggest an undervalued pipeline with potential for late-stage development, leading to investor optimism.
• Expectations of CRSP surpassing earnings estimates for the quarter ending December 2025, along with a positive price target increase, have likely boosted investor confidence.
• Collaboration revenues from partnerships and the anticipated performance in the upcoming earnings report are driving the bullish momentum.
• Overall, the optimistic outlook on CRSP's pipeline, earnings performance, and institutional investor sentiment likely influenced today's strong bullish movement in the stock.

27.01.2026 - CRSP Stock was up 5.8%

• CRISPR Therapeutics' (CRSP) stock demonstrated a robust bullish trend today, posting a notable 11.85% increase despite the company's Q4 2025 earnings and revenue setbacks.
• Speculation surrounding potential acquisitions and the forthcoming investor conferences scheduled for March likely fueled the stock's impressive gain.
• The FDA's recognition of zugo-cel with the Regenerative Medicine Advanced Therapy (RMAT) designation, along with advancements in its gene-editing portfolio such as the commercial launch of Casgevy, have been regarded as favorable drivers for investors. These factors have overshadowed concerns related to widened net losses and internal selling activities.
• Despite lingering internal transactions and financial obstacles, the focus on future clinical progress and pipeline advancements appears to be influencing investor sentiment towards CRISPR Therapeutics. This highlights a preference for long-term growth prospects over immediate profitability considerations.

11.02.2026 - CRSP Stock was down 5.2%

• CRISPR Therapeutics' stock saw a notable decline of over 12% recently.
• Investor sentiment turned negative following the company's announcement of issuing $350 million in convertible notes to raise capital, raising concerns about potential dilution.
• Analysts, however, remain optimistic about CRSP, seeing the drop as a chance for bold investors to consider buying.
• The decision to issue convertible notes is customary in the biotech field to support research and development initiatives, showcasing CRISPR's dedication to advancing its gene-editing programs despite short-term market reactions.